| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DOHH |
| Uniprot No | Q9BU89 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-302aa |
| 氨基酸序列 | MVTEQEVDAIGQTLVDPKQPLQARFRALFTLRGLGGPGAIAWISQAFDDDSALLKHELAYCLGQMQDARAIPMLVDVLQDTRQEPMVRHEAGEALGAIGDPEVLEILKQYSSDPVIEVAETCQLAVRRLEWLQQHGGEPAAGPYLSVDPAPPAEERDVGRLREALLDESRPLFERYRAMFALRNAGGEEAALALAEGLHCGSALFRHEVGYVLGQLQHEAAVPQLAAALARCTENPMVRHECAEALGAIARPACLAALQAHADDPERVVRESCEVALDMYEHETGRAFQYADGLEQLRGAPS |
| 预测分子量 | 32,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DOHH(脱氧羟氨酸羟化酶)重组蛋白的3篇示例参考文献及其摘要概括(注：以下为模拟示例，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**：*Expression and Characterization of Recombinant Human Deoxyhypusine Hydroxylase*
**作者**：Smith J, et al.
**摘要**：研究报道了人源DOHH在大肠杆菌中的重组表达与纯化，证实其通过依赖Fe²⁺的催化机制将脱氧羟氨酸转化为羟氨酸，并分析了酶活性对真核翻译延伸因子eIF5A功能的影响。
2. **文献名称**：*Structural Insights into DOHH-mediated Hypusination Pathway*
**作者**：Lee S, et al.
**摘要**：通过X射线晶体学解析了重组DOHH蛋白的三维结构，揭示了其底物结合位点及催化中心的关键氨基酸残基，为靶向DOHH的药物设计提供结构基础。
3. **文献名称**：*DOHH Knockdown Impairs Cell Proliferation via eIF5A Inactivation*
**作者**：Zhang R, et al.
**摘要**：利用重组DOHH蛋白进行体外功能实验，发现抑制DOHH活性可阻断eIF5A的羟化修饰，导致细胞周期停滞，提示其在癌症治疗中的潜在靶点价值。
---
**注意**：以上为基于DOHH典型研究方向的模拟示例，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索关键词“DOHH recombinant protein”“deoxyhypusine hydroxylase expression”获取。建议结合具体研究方向筛选近年高相关论文。
**Background of DOHH Recombinant Protein**
Deoxyhypusine hydroxylase (DOHH) is a conserved metalloenzyme critical in the post-translational modification of eukaryotic translation initiation factor 5A (eIF5A), a protein essential for cell proliferation and survival. DOHH catalyzes the final step in the hypusine biosynthesis pathway, converting deoxyhypusine-containing eIF5A (eIF5A-Dhp) to its mature, active form (eIF5A-Hpu) via hydroxylation. This modification is unique to eIF5A and is required for its function in facilitating the translation of mRNAs enriched in polyproline motifs, which are inherently challenging for ribosomes to process.
The DOHH enzyme is Fe²⁺- and oxygen-dependent, featuring a non-heme diiron center critical for its catalytic activity. Its structure comprises a helical bundle core with conserved histidine and carboxylate residues coordinating the metal ions. Dysregulation of DOHH or hypusine modification has been linked to various diseases, including cancer, viral infections, and neurodegenerative disorders, highlighting its potential as a therapeutic target.
Recombinant DOHH proteins are typically produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable biochemical and structural studies. Purified DOHH allows researchers to investigate its enzymatic mechanisms, screen inhibitors, and explore its role in cellular processes. Recent structural studies using recombinant DOHH have provided insights into substrate binding and catalysis, aiding drug discovery efforts. However, challenges remain in fully elucidating its regulation and interactions within cellular networks.
Overall, DOHH recombinant protein serves as a vital tool for understanding eIF5A biology and developing therapies targeting hypusine-dependent pathways in disease contexts.
×
